Topical Cannabinoids for Musculoskeletal Syndrome

Overseen By Anne Blaes, MD,MS

Age: 18+

Sex: Any

Trial Phase: Phase < 1

Sponsor: University of Minnesota

Must be taking: Aromatase inhibitors

Must not be taking: Cannabinoids

Disqualifiers: Active skin lesions, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 14

Duration: 2 weeks

24 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial tests cannabinoid creams to help post-menopausal women with hormone-positive breast cancer who suffer from joint pain due to their treatment. The creams, one with more THC and the other with more CBD, aim to reduce pain and improve comfort. Researchers will check if patients are interested, if the creams are safe, and if they work well.

Research Team

Anne Blaes, MD,MS

Principal Investigator

University of Minnesota

Eligibility Criteria

This trial is for adults in Minnesota with hormone receptor-positive breast cancer who have been on aromatase inhibitors for at least 60 days and are experiencing joint pain from the treatment. Participants must be willing to join the Minnesota Medical Cannabis Program, not use other cannabinoids recently, and not plan to start new pain medications or therapies like acupuncture during the study.

Inclusion Criteria

I have experienced significant hand or wrist pain or stiffness in the last week.

Must be willing and able to comply with study visits and procedures

I have had hand or wrist pain for at least 4 weeks.

Exclusion Criteria

I do not have active skin problems on my hands/wrists that could affect cream absorption.

Any known or suspected hypersensitivity to topical cannabinoids

I am currently receiving or planning to start acupuncture on my arms, wrists, or hands soon.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive topical cannabinoid creams for AIMSS treatment

2 weeks

Assessments through day 14

Extension

Participants can choose either Red XS or Violet creams for an additional 2-week period

2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• CBD-dominant
• THC dominant

Trial Overview The CanAroma study tests two topical cannabinoid creams: one THC-dominant and one CBD-dominant, provided by Vireo Health. The goal is to see if these creams are safe, tolerated well, and effective against joint pain caused by breast cancer medication (AIMSS). It's a preliminary step towards larger trials.

Participant Groups

Group I: Violet Experimental Treatment 1 Intervention

Patients receiving CBD-dominant balm

Group II: Red Xs Experimental Treatment 1 Intervention

Patients receiving THC-dominant balm

Who Is Running the Clinical Trial?

University of Minnesota

Lead Sponsor

Trials

1,459

Recruited

1,623,000+